Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids (ASTEROID 2)

• Sponsor: Bayer
• Information provided by (Responsible Party): Bayer

Study Description

Brief Summary:

The study is performed to assess the efficacy of Vilaprisan (BAY1002670) in patients with uterine fibroids compared to placebo and ulipristal. It is also aimed to evaluate the safety of vilaprisan in subjects with uterine fibroids. Further, data on population pharmacokinetic (PK)/ pharmacodynamic (PD) relationship for vilaprisan in subjects with uterine fibroids will be supplemented.

Condition or disease	Intervention/treatment	Phase
Leiomyoma	Drug: Vilaprisan (BAY1002670); Drug: Vilaprisan (BAY1002670; Drug: Ulipristal	Phase 2

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	120 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Randomized, Parallel-group, Double-blind Placebo-controlled and Open Label Active Controlled, Multi-center Study to Assess the Efficacy and Safety of Vilaprisan in Patients With Uterine Fibroids
Study Start Date :	June 2015
Actual Primary Completion Date :	October 2016
Actual Study Completion Date :	October 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm 1 - BAY1002670 + BAY1002670; Vilaprisan (BAY1002670) 2 mg once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)	Drug: Vilaprisan (BAY1002670); Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
Experimental: Arm 2 - Placebo + BAY1002670; Placebo once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)	Drug: Vilaprisan (BAY1002670; Placebo (12 weeks),Vilaprisan (12 weeks)
Experimental: Arm 3 - BAY1002670 + BAY1002670; Vilaprisan 2 mg once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily (12 weeks)	Drug: Vilaprisan (BAY1002670; Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
Experimental: Arm 4 - Placebo+BAY1002670; Placebo once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily(12 weeks)	Drug: Vilaprisan (BAY1002670); Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
Active Comparator: Arm 5 - Ulipristal + Ulipristal; Ulipristal 5 mg once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)	Drug: Ulipristal; Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
Active Comparator: Arm 6- Placebo + Ulipristal; Placebo once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)	Drug: Ulipristal; Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
Active Comparator: Arm 7- Ulipristal + Placebo; Ulipristal 5 mg once daily (12 weeks), treatment break, Placebo once daily (12 weeks)	Drug: Ulipristal; Ulipristal (12 weeks), treatment break, Placebo (12 weeks)

Outcome Measures

Primary Outcome Measures :

1. Amenorrhea (yes/no) [ Time Frame: From day 7 to day 84 of treatment. ]
   Defined as no scheduled or unscheduled bleeding/spotting after end of the initial bleeding episode until the end of the respective treatment period.

Secondary Outcome Measures :

1. Number of bleeding days [ Time Frame: Up to 32 weeks ]
2. Time to onset of controlled bleeding [ Time Frame: Up to 28 weeks ]
3. Percent change in volume of largest fibroid from baseline to end of treatment. [ Time Frame: Baseline and up to 28 weeks ]
4. Endometrial histology [ Time Frame: Baseline and up to 40 weeks ]
   (Frequency of the following categories: benign endometrium, endometrial hyperplasia, malignant neoplasm)
5. Endometrial thickness measured by transvaginal ultrasound. [ Time Frame: Baseline and up to 40 weeks ]

Eligibility Criteria

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 50 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Women, 18 to 50 years of age at the time of screening
• Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at screening with at least 1 fibroid with largest diameter >/=3.0 cm
• Heavy menstrual bleeding (HMB) >80 mL documented by menstrual pictogram (MP) in a bleeding episode during the screening period. Women who did not suffer from perceived HMB during the 3 months prior to Visit 1 due to any effective medical treatment, e.g. with a hormonal contraceptive, are not considered appropriate candidates and should not undergo further screening procedures. Women suffering from perceived HMB despite medical treatment, e.g. with a hormonal contraceptive, are appropriate candidates for further screening, if rules on stopping prior medication are followed. Heavy menstrual bleeding /HMB) > 80 mL should be documented within 10 consecutive days.
• Good general health (except for findings related to uterine fibroids) as proven by medical history, physical and gynecological examinations, and laboratory test results
• Normal or clinically insignificant cervical smear not requiring further follow-up. Human papilloma virus (HPV) testing in subjects with atypical squamous cells of undetermined significance (ASCUS) can be used as an adjunctive test. Subjects with ASCUS can be included if they are negative for high-risk HPV strains.
• An endometrial biopsy performed during the screening period, without significant histological disorder such as endometrial hyperplasia (including simple hyperplasia) or other significant endometrial pathology.
• Use of an acceptable nonhormonal method of contraception (i.e. either male condom, cap, diaphragm or sponge, each in combination with spermicide) starting at the bleeding episode following the screening visit 1 (Visit 1) until the end of the study. This is not required if safe contraception is achieved by a permanent method, such as bilateral fallopian tube blockage of the subject or vasectomy of the partner(s).

Exclusion Criteria:

• Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation before start of treatment)
• Uterine fibroid with largest diameter >10.0 cm
• Hypersensitivity to any ingredient of the study drugs
• Hemoglobin values </= 6 g/dL or any condition requiring immediate blood transfusion (subjects with hemoglobin values </=10.9 g/dL will be offered iron supplementation).
• Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug
• Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
• Abuse of alcohol, drugs, or medicines (e.g. laxatives)
• Use of other treatments that might interfere with the conduct of the study or the interpretation of the results
• Undiagnosed abnormal genital bleeding.

Contacts and Locations

  Show 64 Study Locations

Sponsors and Collaborators

Bayer

Investigators

Layout table for investigator information

Study Director:	Bayer Study Director	Bayer

More Information

Additional Information:

Click here and search for drug information provided by the FDA.  Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. 

Layout table for additonal information

Responsible Party:	Bayer
ClinicalTrials.gov Identifier:	NCT02465814 History of Changes
Other Study ID Numbers:	17541; 2014-004221-41 ( EudraCT Number )
First Posted:	June 9, 2015
Last Update Posted:	November 22, 2016
Last Verified:	November 2016

Keywords provided by Bayer:

Uterine fibroids; Heavy Menstrual Bleeding

Additional relevant MeSH terms:

Layout table for MeSH terms

Leiomyoma; Myofibroma; Neoplasms, Muscle Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Connective Tissue	Connective Tissue Diseases; Ulipristal acetate; Contraceptive Agents, Female; Contraceptive Agents; Reproductive Control Agents; Physiological Effects of Drugs